SPORE: DF/HCC SPORE in GASTROINTESTINAL CANCER

孢子：胃肠癌中的 DF/HCC 孢子

• 批准号: 9112885
• 负责人: Adam Joel Bass
• 金额: $ 216.2万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-31 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9112885
• 关键词: Address; BRAF gene; Basic Science; Bioinformatics; Biological; Biometry; Boston; Cancer Biology; Cancer Center; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Colorectal Cancer; Communication; Dana-Farber Cancer Institute; Databases; Detection; Development; Diagnosis; Diagnostic; Dysplasia; Dysplasia in Barrett' s Esophagus; Early Diagnosis; Evaluation; Funding; General Hospitals; Genetic; Genomics; Goals; Hospitals; Imaging technology; Institutes; Institution; Investigation; Israel; KRAS2 gene; Knowledge; Malignant neoplasm of gastrointestinal tract; Massachusetts; Medical center; Mentors; Modeling; Mutation; PDGFRA gene; Pathology; Patients; Pediatric Hospitals; Population; Population Sciences; Prevention; Public Health Schools; Recording of previous events; Regimen; Reporting; Research Personnel; Resistance; Resources; Role; Scientist; Signal Pathway; Specialized Program of Research Excellence; Specimen; Technology; Therapeutic; Time; Tissues; Translating; Translational Research; Translations; Vitamin D; Woman; Work; anticancer research; base; cancer prevention; cancer survival; cancer therapy; career development; clinical decision-making; clinically relevant; colon carcinogenesis; design; effective therapy; flexibility; gastrointestinal; improved; improved outcome; innovation; inter-institutional; kinase inhibitor; medical schools; molecular imaging; mutant; new therapeutic target; novel; novel therapeutic intervention; novel therapeutics; outcome prediction; patient population; prevent; prognostic; programs; public health relevance; repository; research and development; resistance mechanism; response; success; therapy resistant; tool; translational study; tumor progression

DESCRIPTION (provided by applicant): This application represents the competitive renewal of a Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer originating from the Gastrointestinal (GI) Malignancies Program of the Dana-Farber/Harvard Cancer Center (DF/HCC). The main goal of the DF/HCC SPORE in GI Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of gastrointestinal malignancies. The DF/HCC SPORE in GI Cancer includes researchers from all Harvard-affiliated hospitals and institutions: the Dana-Farber Cancer Institute, the Brigham and Women's Hospital, the Massachusetts General Hospital, the Beth Israel Deaconess Medical Center, Children's Hospital of Boston, Harvard Medical School, Harvard School of Public Health, and Broad Institute. Five major projects are proposed including: 1) Molecular imaging for detection of high grade dysplasia in Barrett's Esophagus; 2) Defining the role of vitamin D in colorectal carcinogenesis and cancer survival; 3) Identifying novel therapeutic strategies for KRAS-mutant colorectal cancer; 4) Overcoming resistance to RAF inhibition in BRAF-mutant colorectal cancer; and 5) Overcoming Resistance to KIT/PDGFRA Inhibition in GIST. These projects will be integrated by three cores: 1) Administration, Evaluation & Planning; 2) Tissue & Pathology; and 3) Biostatistics & Bioinformatics. The SPORE application outlines a Developmental Projects Program that includes a plan of selection of new projects and documents 18 highly innovative and productive developmental projects that have been supported during the current funding cycle. We also include a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in GI cancer and report on our success in supporting and mentoring 15 young investigators during the current funding cycle. The projects and cores proposed in this application are highly integrated with present DF/HCC core resources, and involve key collaborations with investigators from other existing SPOREs and cancer centers. The renewal of this GI SPORE at DF/HCC will combine leading Harvard researchers in basic, translational, and clinical sciences into a program that has the focus and coordination required to produce meaningful advances in the diagnosis, treatment, and prevention of GI cancers.

描述(由申请者提供)：本申请代表Dana-Farber/哈佛癌症中心(DF/HCC)胃肠道(GI)恶性肿瘤专项研究计划(SPORT)的竞争性续展。胃肠道肿瘤的DF/HCC孢子的主要目标是将生物学和技术的进步转化为胃肠道恶性肿瘤的预防、诊断、预后预测和治疗方面的进步。胃肠道癌症中的DF/HCC孢子包括来自所有哈佛附属医院和机构的研究人员：达纳-法伯癌症研究所、布里格姆妇女医院、马萨诸塞州总医院、贝丝以色列女执事医疗中心、波士顿儿童医院、哈佛医学院、哈佛大学公共卫生学院和布罗德研究所。提出了五个主要项目，包括：1)分子成像检测Barrett‘s食道高度不典型增生；2)确定维生素D在结直肠癌发生和癌症生存中的作用；3)寻找KRAS突变结直肠癌的新治疗策略；4)在BRAF突变结直肠癌中克服对RAF抑制的抵抗；以及5)在GIST中克服对KIT/PDGFRA抑制的抵抗。这些项目将由三个核心组成：1)管理、评估和规划；2)组织和病理学；以及3)生物统计学和生物信息学。孢子申请概述了一项发展项目方案，其中包括一项选择新项目的计划，并记录了在当前供资周期中得到支持的18个极具创新性和生产性的发展项目。我们还包括一个职业发展计划，该计划概述了一种识别和支持GI癌症领域有才华的年轻研究人员的机制，并报告了我们在当前资金周期内成功支持和指导了15名年轻研究人员的情况。本申请中提出的项目和核心与现有的DF/HCC核心资源高度集成，并涉及与来自其他现有孢子和癌症中心的研究人员的关键合作。DF/HCC的这一GI孢子的更新将把哈佛大学在基础、翻译和临床科学方面的领先研究人员结合到一个项目中，该项目具有在GI癌症的诊断、治疗和预防方面取得有意义的进展所需的重点和协调。